Title |
Designer bacteria as intratumoural enzyme biofactories
|
---|---|
Published in |
Advanced Drug Delivery Reviews, September 2017
|
DOI | 10.1016/j.addr.2017.09.012 |
Pubmed ID | |
Authors |
Panos Lehouritis, Glenn Hogan, Mark Tangney |
Abstract |
Bacterial-directed enzyme prodrug therapy (BDEPT) is an emerging form of treatment for cancer. It is a biphasic variant of gene therapy in which a bacterium, armed with an enzyme that can convert an inert prodrug into a cytotoxic compound, induces tumour cell death following tumour-specific prodrug activation. BDEPT combines the innate ability of bacteria to selectively proliferate in tumours, with the capacity of prodrugs to undergo contained, compartmentalised conversion into active metabolites in vivo. Although BDEPT has undergone clinical testing, it has received limited clinical exposure, and has yet to achieve regulatory approval. In this article, we review BDEPT from the system designer's perspective, and provide detailed commentary on how the designer should strategize its development de novo. We report on contemporary advancements in this field which aim to enhance BDEPT in terms of safety and efficacy. Finally, we discuss clinical and regulatory barriers facing BDEPT, and propose promising approaches through which these hurdles may best be tackled. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 20% |
Ireland | 1 | 10% |
United States | 1 | 10% |
Unknown | 6 | 60% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 9 | 90% |
Scientists | 1 | 10% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 51 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 13 | 25% |
Researcher | 13 | 25% |
Student > Master | 5 | 10% |
Student > Bachelor | 4 | 8% |
Student > Doctoral Student | 3 | 6% |
Other | 7 | 14% |
Unknown | 6 | 12% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 10 | 20% |
Chemistry | 8 | 16% |
Agricultural and Biological Sciences | 6 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
Engineering | 3 | 6% |
Other | 11 | 22% |
Unknown | 9 | 18% |